Immunexpress.com

SEATTLE, May 18, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by Dr. Russell R. Miller, III…

Read More
Immunexpress.com

Results of a Pilot Study of SeptiCyte™ LAB in the Pediatric Setting Published in Critical Care Medicine SEATTLE, Sept. 22, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and patients at risk of sepsis, announced today the publication, in Critical Care Medicine, of data demonstrating the ability…

Read More
Immunexpress.com

SEATTLE, May 11, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the upcoming American Thoracic Society International…

Read More

European Society for Intensive Care Medicine October 1-5, 2016 Milan, Italy. Dr Mahdad Noursadeghi, of University College London presented preliminary results in a validation trial of an Immunexpress developed signature for the diagnosis of bacterial infection in patients presenting to ER, and for a second signature in the same validation cohort for differentiating bacterial from…

Read More

36th International Symposium on Intensive Care and Emergency Medicine March 15-18, 2016 Brussels, Belgium. Russ Miller, of Intermountain Healthcare presented data on the market need for accurate sepsis diagnostics using results from the IXP VENUS trial showing that expert physicians agree on a diagnosis of sepsis in between 60 to 80% of cases, highlighting the…

Read More
Immunexpress.com

SEATTLE, Feb. 22, 2017 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and healthcare providers, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of SeptiCyte™ LAB as an aid in differentiating infection-positive (sepsis) from infection-negative (SIRS) systemic inflammation…

Read More
Immunexpress.com

Results from an investigation of over 40 datasets published in Scientific Reports SEATTLE, June 6, 2017 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced the publication, in Scientific Reports, of data demonstrating the ability of a four-biomarker blood signature to discriminate viral…

Read More

International Sepsis Forum 2017 11-13 September, 2017 Paris, France Dr Leo McHugh presented an algorithmic method for interpreting the performance of high accuracy diagnostics when judged against clinical diagnoses known to contain uncertainty. This is the first public release of this method and associated open-course software for the diagnostics community. The method and software has…

Read More
Immunexpress.com

Mechelen (Belgium)/Seattle (United States), 24 January 2018 – Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART) and Immunexpress Pty Ltd (‘Immunexpress’), a host response molecular diagnostic company, committed to improving clinical and economic outcomes for suspected sepsis patients, today announce that they have entered into a partnership agreement aimed at the…

Read More
Immunexpress.com

Industry veteran brings a successful track record fundraising and launching commercial products Appointment strengthens the leadership team and positions the company for its targeted commercial launch   SEATTLE, April 10, 2018 – Immunexpress, Inc. today announced the appointment of Rolland D. Carlson, Ph.D., as chief executive officer, effective April 9, 2018. Dr. Carlson most recently…

Read More